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ABSTRACT
Gene targeting allows precise tailoring of the mouse
genome such that desired modifications can be
introduced under precise temporal and spatial con-
trol. This can be achieved through the use of site-
specific recombinases, which mediate deletion or
inversion of genomic DNA flanked by recombi-
nase-specific recognition sites, coupled with gene
targeting to introduce the recombinase recognition
sites at the desired genomic locations within the
mouse genome. The introduction of multiple modi-
fications at the same locus often requires use of
multiple recombination systems. The most com-
monly used recombination system is Cre/lox. We
here evaluated in vivo the ability of PhiC31 phage
integrase to induce a genomic deletion in mouse.
We engineered a self-excision cassette, modeled
after one previously designed for Cre, containing
a positive selection marker and PhiC31 driven by a
testis-specific promoter, all flanked by PhiC31 spe-
cific attP/B sites. We found in vivo PhiC31 mediated
self-excision in 38% of transmitted alleles, although
18% of these showed evidence of imprecise dele-
tion. Furthermore, in the 69% of un-recombined
cassettes, sequence analysis revealed that PhiC31
mediated an intra-molecular deletion of the attB site
preventing any subsequent recombination. This
study demonstrates that PhiC31 can be used to
automatically remove Neo, in the male chimera
germline, although it is not as efficient or as accu-
rate as Cre.
INTRODUCTION
Conditional mutagenesis requires precise engineering
of the locus under investigation. This generally involves
positioning two loxP sites surrounding the region to be
deleted. Cre recombinase, under speciﬁc temporal and
spatial control, then mediates site-speciﬁc recombination
between the two loxP sites, removing the intervening
sequence. The Cre/loxP system is the main player in
manipulating the mouse genome in vivo, because it is
more eﬃcient than the Flpe/Frt system (1). Since the intro-
duction of this protocol, hundreds of loxP conditional
mouse lines and Cre-driver lines have been created.
There are conditions in which it is desirable to introduce
more than one modiﬁcation into the same locus controlled
by diﬀerent temporal and tissue-speciﬁc drivers. For
example, since the introduction of BAC clones for the
construction of gene targeting vectors (2,3) it is possible
to introduce multiple modiﬁcations, often associated with
multiple positive selection cassettes. For this reason, eﬃ-
cient and diverse site-speciﬁc recombinases are often
needed.
The Streptomyces phage, PhiC31, integrates its genome
into the bacterial host using a site-speciﬁc integrase, which
catalyzes an integration reaction between the attP/attB
sites (attachment site Phage/attachment site Bacteria)
(4); the sites generated after recombination are called
attL and attR (Figure 1A). PhiC31 integrase belongs to
the family of serine recombinases along with gd and Hin
resolvase (5). Cre and Flpe are members of the tyrosine
recombinase group and their mechanisms of action have
been well reported. The crossover between the DNA–
protein complexes proceeds through a Holliday junction
intermediate that is resolved through a concerted rejoining
of the opposite strands. In contrast to tyrosine recombi-
nases, the mechanism of action of the serine recombinases
is less well-characterized: the recombinase binds the recog-
nition sites and generates a staggered double-strand break;
then catalytic subunits rotate and rejoin and repair the
broken ends. However, the details of these reactions are
still not well-deﬁned (5).
Because the reaction of PhiC31 involves two diﬀerent
sites and the resulting recombination products, attL and
attR, are not a substrate for the opposite reaction in the
absence of bacterial cofactors, the reaction in mammalian
cells is unidirectional (4). The minimal size of the two
sites in bacterial cells is 39 bp for the attP and 34 bp for
the attB (6). Both sites share an identical 3-bp long central
core ‘TTG’, where the crossover occurs. The arms, unlike
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repeats, only partially conserved. PhiC31 has already
been extensively tested in vitro as well as in vivo in mam-
malian cells (7). Its biochemical properties led many
groups to use it to insert single copy transgenes in the
mouse genome as a nonviral approach for gene therapy
(8). In this way, PhiC31 has been successfully used to
achieve therapeutic levels of Factor IX in mouse in vivo
(8) or to target single copy transgenes in mouse ES cells
























































Figure 1. Schematic representation of PhiC31 self-excision. (A) Mechanism of integration of the PhiC31 phage into the bacterial genome. PhiC31
integrase mediates the integration reaction between the attachment site on the phage (attP) and the one in the bacterial genome (attB). The two sites
are diﬀerent, upon integration, the excision reaction is mediated exclusively by an excision factor produced by the bacterial cell, for this reason the
reaction in mammalian cells is unidirectional. Upon recombination the newly formed hybrid sites are called attL and attR. (B) Mechanism of
the SEC. The targeted allele contains a positive selection cassette (neomycin phospho-transferase), ﬂanked by two attB/P sites. PhiC31 expressed in
the chimeric male testes will mediate the automatic removal of the cassette during the passage through the male germline. In the F1 generation, three
diﬀerent outcomes are possible: no germline transmission of the targeted allele, the targeted allele will be transmitted without Neo and an attL site
‘scar’ will be present or the cassette will be transmitted unrecombined. The black color in the mouse body indicates the presence of the targeted allele.
(C) Schematic representation of the PhiC31 SEC. The oligonucleotides used for the screening of the construct are represented above and below the
SEC. Oligonucleotides 156–157 amplify the wild-type allele and the recombined allele containing the fused attP/B site.
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oriented in the same direction in cis, inducing the deletion
of the intervening sequence (10).
Introducing a modiﬁcation in the mouse genome
through gene targeting requires a positive selection cas-
sette (usually a Neomycin phospho-transferase gene or
Neo
r) to identify the correctly targeted ES cells clones.
Several reports have found that the presence of Neo
r cas-
sette often generates unwanted and unanticipated results
(11–14). For this reason, following its use as a selection
cassette, it is important to remove Neo
r, from the targeted
locus, using a site-speciﬁc recombinase. To reduce manip-
ulation of ES cells, the Flpe/Frt system is often used
in vivo for this purpose. The Flpe ‘deleter’ mouse (15)
removes the Neo
r selection cassette, ﬂanked by two Frt
sites. Nonetheless, several months of breeding are usually
required to remove the selection cassette and then to breed
out Flpe recombinase. In our laboratory, we have pre-
viously generated a self-excising selection cassette using
the Cre/loxP system that is eliminated during passage
through the male germline (16). This cassette cannot be
used to make a conditional allele carrying two other loxP
sites and when a cassette was engineered using Flpe/Frt
system it was largely ineﬃcient (Bunting,M., Wu,S. and
M.R.C., unpublished data).
To test PhiC31 recombinase in vivo, a self-excision cas-
sette (SEC) was generated. This assay allows evaluation of
the eﬃciency of PhiC31 in removing the selection marker,
Neo
r, while passing through the chimera germline. It is
important to observe that it captures single recombination
events through the germline, thus allowing a better evalua-
tion of its activity. At the same time, if it works, it can be
used to craft new targeted conditional alleles in conjunc-
tion with the Cre/loxP system.
We found that PhiC31 recombinase excised the selec-
tion cassette in 38% of analyzed mice. We were able to
show that unlike Flpe or Cre, PhiC31 is not 100% precise
in rejoining the attP/B sites, leading to variable deletions
of the newly generated hybrid site. Furthermore, in 69%
of unrecombined cassettes, PhiC31 induced an intra-
molecular deletion of the attB site that prevented further
recombination.
MATERIALS AND METHODS
The SEC was engineered following standard cloning pro-
cedures. A plasmid containing the PhiC31 wild-type
sequence was a kind gift of Margaret Smith. The original
sequence was PCR-modiﬁed to add a nuclear leading
signal (NLS) to the C-terminal end of the protein (1).
To prevent functional expression of the PhiC31 plasmid
in bacteria, an intron, the large T intron from SV40, was
introduced into the PhiC31 coding sequence. Large T
intron was PCR-ampliﬁed, using Cre SEC as a template,
with the following oligonucleotides (24a 50GTAAGTGC
TTCTTCCTTAAT30 and 20 50CTAAAATACACAAAC
AATTAG30) that allowed subcloning into the PhiC31
Eco47III restriction site. The entire modiﬁed PhiC31 was
sequenced and found to be correct except for a missense
mutation (c.90C>T). Because this change did not modify
the corresponding amino acid residue, it was left
unchanged. The attB and attP sites 85-bp long were gen-
erated by re-annealing oligonucleotides. PhiC31 modiﬁed
sequence and its sites have been subcloned, replacing Cre
and loxP sites in the original Cre SEC. This cassette was
inserted in a targeting vector containing 10 kb of homol-
ogy region to the Bmi1 locus, which we previously success-
fully targeted in mouse ES cells (17). Chimeras generated
by blastocysts injection were bred with C57Bl/6J females
and 173 mice derived from these crosses were analyzed to
check for the recombined and unrecombined events.
Oligonucleotides 156–157 (50TGACACACACACAATG
GGAC30,5 0CGTGTGTTTATCAGCCATCAG30) ampli-
ﬁed the wild-type and the recombined allele, while they
were unable to amplify the unrecombined allele.
Oligonucleotides Neo1-2 (50 GCAGGCATCGCCATGG
GTC30,5 0GGACTGGCTGCTATTGGGCG30) con-
ﬁrmed the presence of the SEC in the unrecombined
mice. To check for random deletions, we used the follow-
ing oligonucleotides: 31 50AGGTCTCTGTGAGGCTGG
TAA30, Phi1 50ATGACACAAGGGGTTG TGAC30,
Phi2 50TCTAAACCTTCCTCTTCTTC30,3 05 0 CCTTC
TTGACGAGTTCTTCTGA30.
Each PCR product was puriﬁed with EXO-SAP (USB)
using manufacturer recommendations and then sequenced
by the Sequencing Core Facility at the University of Utah.
For the recombined allele, the recombined band was gel
puriﬁed and then sent directly for sequencing.
RESULTS
PhiC31 was tested in vivo by modifying an assay already
established in our lab: two loxP sites ﬂank an ES cell
positive selection cassette containing a Neo
r under control
of a general promoter derived from the large subunit
DNA–RNA polymerase II, and Cre recombinase under
control of a testis-speciﬁc promoter (tACE) (16). This
SEC has been successfully used in many diﬀerent labora-
tories to automatically remove Neo
r through the chimera
germline, leaving only a residual loxP site. As a result, the
ﬁnal modiﬁcation introduced into the genome is left
‘clean’ without any negative eﬀect of the Neo
r gene or of
its promoter on the locus under investigation. The same
strategy was used to test PhiC31, replacing Cre/loxP sites
with PhiC31 and its attB/P sites (Figure 1B–C). The
wild-type PhiC31 sequence was modiﬁed to add to the
C-terminal region, a NLS that has been shown in mam-
malian cells to improve eﬃciency of recombination (1)
compared to the wild-type sequence. To prevent cassette
self-excision during cloning procedures the large T intron
from SV40 virus was introduced into the PhiC31 coding
sequence.
Although minimal sizes of attP/B sites were established
in bacterial cells as 39 and 34 bp, respectively, we decided
to use 85-bp long sites that have already been proven to
eﬃciently mediate recombination in mammalian cells (1).
This cassette was inserted into a targeting vector and
successfully targeted into the Bmi1 locus (Figure 2).
Male chimeras from one ES cell line (ES cell line 1h25)
were bred to wild-type females and progeny assayed by
PAGE 3 OF 8 Nucleic Acids Research, 2008, Vol. 36,No. 20 e134PCR for transmission of the targeted allele (Table 1). To
evaluate the eﬃciency of recombination, a PCR-based
screening was used to identify in each F1 generation
mouse, whether the cassette was transmitted recombined
or unrecombined, as well as the wild-type allele. Two oli-
gonucleotides (156–157) ﬂanking the insertion site of the
SEC, amplify the wild-type sequence and the recombined
attP/B site. The unrecombined allele is not ampliﬁed
because of its large size. Another pair of oligonucleotides
inside the Neo gene was designed to conﬁrm the presence
of the cassette if unrecombined (Figure 1C). We screened
173 progeny from 14 chimeras. The SEC was transmitted
intact to 58/173 mice in the F1 progeny (Table 1). In
 62% (36/58) of mice, the SEC was transmitted intact
not recombined in 22/58 (38%) it was deleted. However,
in 4/22 recombined cases, the recombined band was
slightly smaller than expected. Sequence analysis revealed
that in these four samples the recombination product con-
tained an intra-molecular deletion of 13, 17, 38 and 64 bp
of the newly created attL site spanning the TTG recombi-
nation site (Figure 3A and B). These four mice were gen-
erated from four diﬀerent chimeras. In 18/22 mice, the size
of the PCR product conﬁrmed that recombination in the
chimera germline generated the expected product
among the attP and attB sites. We analyzed by sequencing


















Figure 2. Targeting strategy. (A) Schematic representation of the Bmi1 locus and the targeting vector containing the PhiC31 SEC. We indicated the
positions of the restriction enzymes and the probes used (N, NcoI; B, BglII). (B) Southern blot analysis of the electroporated ES clones, showing
the results of the 30 and Neo probe. The arrows indicate the wild-type and the targeted alleles.
Table 1. SEC recombination analysis in the F1 progeny
Chimeras F1 progeny
Unrecombined Recombined No germline
transmission
Deleted attB WT attB/P Precise Deleted
7001 – – – – 7
7002 – – 1 – 7
7003 2 1 1 1 5
7008 – – – – 8
7009 – – 4 – 4
7010 – – – – 6
7012 4 – 2 1 10
7013 – – – – 9
7014 1 2 1 1 4
7015 5 3 4 1 17
7016 – – – – 16
7017 6 1 1 – 8
7018 4 2 1 – 8
7021 3 2 3 – 6
36 22
Total 58 115
In the left column are indicated the chimeric males crossed with C57Bl/
6 females to generate 173 mice in the F1 progeny. In detail, from left to
right are indicated per each chimera the number of mice with the SEC
unrecombined with a deleted attB or WT attB and attP, and the
number of mice with a WT recombination product or deleted. In the
right column are indicated the number of mice who did not inherit
the targeted allele.
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base pair.
To rule out the presence of deletions or rearrangements
in the cassette, all the unrecombined alleles were PCR
ampliﬁed, using overlapping oligonucleotides to cover
the whole cassette (Figure 1C). The PCR product across
the attB site showed an unexpected variety in size
(Figure 4A). All the attB sites from the unrecombined
mice were sequenced and found to be deleted in 25/36
mice. Deletions ranged from 5 to 111 bp, always including
the TTG recombination site and some including part of
the polyadenylation signal of Neo located at the 30-end
of the attB site (Figure 4B and C). In three mice, the
deletion was associated with the presence of 1, 4 and 10
extra nucleotides. The attP sites were also sequenced and
found normal in all 36 unrecombined mice.
No other apparent deletion was present in the PCR
products covering the rest of the cassette.
To investigate when the attB deletions occurred, the
targeting vector plasmid that was electroporated in ES
cells, the two correctly targeted ES clones (one of them
was injected into blastocysts) and the tail DNA of two
chimeras were PCR-ampliﬁed and sequenced. In all
cases, the PCR products and the corresponding sequences
were wild-type (Figure 4C).
To evaluate whether male mice with an intact SEC, and
without an attB deletion, were able to recombine in the
next-generation, one mouse was crossed with C57/Bl6
females. In 8/17 mice, the allele was recombined (three
alleles showed a slightly smaller band than the control),
while in 9/17 the cassette remained intact, even tough four
alleles showed a smaller band for the attB site (Table 2).
These results conﬁrmed that the intact SEC is still able to
recombine in the F2 generation although with the same
outcome we observed in the F1 generation.
DISCUSSION
We have demonstrated that PhiC31 can be successfully
used in vivo in the mouse to remove the Neo
r selection
cassette. This cassette can be used along with the Cre/
loxP system to generate a conditional allele carrying the
desired modiﬁcation minimizing the possibility of negative
eﬀects of Neo
r. At the same time, using this assay we were
able to demonstrate that the PhiC31 had an eﬃciency of
 38% in recombining out the SEC sequence, indicating
that the integrase is not as eﬃcient as Cre in vivo in the
same assay (Cre was always 100% eﬃcient, in diﬀerent
constructs generated in our lab as well as in other labs).
It is interesting to observe that when the Flp/Frt SEC was
generated, using the same general conﬁguration, it did not
work (Bunting and Wu, unpublished data). After several
changes and modiﬁcations a successful Flp/Frt SEC was
engineered (Wu, manuscript in preparation), indicating
that the overall recombination eﬃciency of the Flp/Frt
system is lower that Cre and PhiC31 recombinases.
An unexpected ﬁnding was the imprecise recombination

















7009N8       AGAAGCGGTT TTCGGGAGTA GTGCCCCAAC TGGGGTAACC TTTGGGCTCC CCGGGCGCGT ACTCCACCTC ACCCATCTGG TCCA
7014N104     AGAAGCGGTT TTCGGGAGTA GTGCCCCAAC TGG~~~~~~~ ~~~~~~CTCC CCGGGCGCGT ACTCCACCTC ACCCATCTGG TCCA
7015N4       AGAAGCGGTT TTCGGGAGTA GTGCCCCAAC T~~~~~~~~~ ~~~~~~~~CC CCGGGCGCGT ACTCCACCTC ACCCATCTGG TCCA
7012N14      AGAAGCGGTT TTCGGGAGTA GTGCCCCAAC TGG~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~CCCATCTGG TCCA
7003N3       AGAAGCGGTT TTC~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~TGG TCCA
attP half




Figure 3. Deletion products of PhiC31 self-excision. (A) Sequence alignment of the predicted fusion product upon recombination between an attP/B
site compared with four deletions. The deletions were 13, 17, 38 and 64 bp and were recovered in four mice born from four diﬀerent chimeras. (B)
Electropherogram of one deleted allele (7003N3) compared to the correct recombination product (7009N8).
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Previous studies have documented such imprecision
when PhiC31 was used to insert a transgene in pseudo-
attP sites in mouse or in human cells (7). While those
results could be easily explained by substitutions present
in the pseudo-attP sites, our experiments clearly demon-
strate the imprecise nature of recombination with the ori-
ginal sites in the context of mammalian cells. Moreover, in
25/36 unrecombined events, the attB site showed a series
of deletions encompassing the TTG recombination site
that prevented any further rearrangements with the attP
site. To identify the source of the deletions, the original
targeting vector plasmid, the attB sites from the two
targeted ES cell clones and the DNA from two tail













































10 11 12 13 14 15 16 17 18 19 20
PCR size   378       373    367   366   358    345   320   271 378      373  369  367 366  358  378  345  320  279
WT WT 33 58 99 20 12 59 1 1
Figure 4. PCR analysis of the attB sites. (A) Representative PCR products of the attB sites from 15 diﬀerent DNAs containining the cassette
unrecombined, oligos used were 157–30. Lanes 1, 2, 10, 11, 17 represent the wild-type product obtained from one of the chimeras (7014), one F1
progeny mouse where the cassette was still intact and no deletion was found, two targeted ES clones and the targeting vector plasmid. Lanes 3–9, 12–
16, 18–20 are F1 progeny mice containing diﬀerent deletions of the attB site. Some of the PCR product from the same mice was loaded on both gels
for comparison. Beneath each lane is the size of the deletion and the size of the PCR product. (B) Sequence comparison of the original targeting
vector sequence (attB), two correctly targeted ES cells lines (1h17–1h25), two chimeras (7014, 7015), eight intact sequences from F1 progeny mice
(from 7018N4 to 7017N4), 19 deleted sequences from F1 progeny mice (from 7012N1 to 7017N7). 7021N9 and 7021N3 have both a deletion and 1
and 4 extra base pairs that are not matching any sequence at the junctions. (C) Electropherogram of one (7021N5) deletion compared to the correct
attB site, sequenced from the targeting vector plasmid.
Table 2. SEC recombination analysis in the F2 progeny
F1 male F2 progeny
Unrecombined Recombined No
transmission
Deleted attB WT attB/P Precise Deleted
7014N12 4 5 5 3 13
Total 17
In the left column is indicated the male (derived form the chimera 7014)
crossed with C57Bl/6 females to generate 30 mice in the F2 progeny.
In detail, from left to right are indicated the number of mice with the
SEC unrecombined with a deleted attB or WT attB and attP, and
the number of mice with a WT recombination product or deleted.
In the right column are indicated the number of mice who did not
inherit the targeted allele.
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targeting vector contained a ‘population’ of deleted attB
fragments. The correct sequences of the two correctly
targeted ES cell clones (including the one injected into
blastocysts) and the DNA extracted from the tail chimeras
conﬁrmed that deletions in the attB site do not represent a
mitotic error. Because the only tissue with abnormal attB
sites was the chimera’s testes, where PhiC31 is transcribed,
this provides strong evidence that PhiC31 integrase has
spurious activity in the mammalian genome. It is note-
worthy to observe that the same chimera gave rise to all
diﬀerent recombination products and the same attB dele-
tions were present in mice coming from diﬀerent chimeras,
indicating that every deletion represents a unique event
(Table 1). AttP/B deletions have been reported before in
an experiment rearranging the centromere of the human Y
chromosome (18). The probable cause for these events is
in the intrinsic mechanism of the serine recombinases
where the presence of the double-strand breaks recruits
the cellular DNA-repair system leading to the repair of
intermediate products of recombination.
Remarkably, only the attB site was mutagenized, as we
found virtually no mutations in the attP site or anywhere
in the rest of the cassette. This could provide the explana-
tion for the well-known asymmetry in the PhiC31-attP/B
system (9,19): every time PhiC31 integrase was used to
insert a transgene in mammalian cells and the attB was
the docking site with an incoming plasmid containing an
attP site, the frequency of integration was equal to the
frequency of random integration. On the other hand, the
frequency of the opposite conﬁguration, attP site as dock-
ing site with an incoming attB site, was 30–40% higher
than random integration (9). It has been shown (20) that
the PhiC31 integrase binds the attB site adopting a speciﬁc
conformation that allows synapse formation with attP to
recombine the two sites. We can speculate that attB bind-
ing in the context of the mammalian genome can be ‘dis-
turbed’ or can be constrained by chromatin conﬁguration
or the presence, for example, of methylated CpG, which
would prevent a correct synapse formation with the attP
site leading to a ‘premature’ recombination with conse-
quent internal deletion of the attB itself.
Several reports have raised concerns about the safety
of using PhiC31 in vivo. In one experiment (21), stable
expression of PhiC31 integrase in human ﬁbroblasts was
associated with chromosomal aberrations, while another
report (22) showed that transient expression in the mouse
liver was associated with the appearance of dysplastic
cells. In a diﬀerent experiment, we attempted to generate
a PhiC31 general ‘deleter’ targeted to the large subunit of
the RNA polymerase II (Polr2a) locus that has a very high
targeting eﬃciency ( 60%) (Thomas,K. and M.R.C.,
unpublished data). We used a very strong promoter to
drive the expression of PhiC31 that has already been
shown to be able to generate inter-chromosomal translo-
cations using Cre (23); however, in three diﬀerent electro-
poration experiments, we were not able to recover a single
positive targeted clone out of 432 clones. This suggests
that PhiC31 when highly expressed could have a ‘toxic’
eﬀect in the context of the mammalian genome.
In spite of these results, we did not detect any negative
eﬀect in mice harboring the recombined or unrecombined
allele in homozygous conﬁguration. Homozygous mice
were fertile when kept alive for up to 1 year, and did
not show any evident sign of disease. We can not rule
out that random deletions are introduced into the
genome, but at least in the region surrounding the SEC
we analyzed, there are no other evident abnormalities.
In our experiment, PhiC31 is expressed only in testis and
in the case of the recombined alleles the expression itself is
self-limiting; moreover, in the presence of imbalanced
chromosomal translocations it is conceivable that the
sperm maturation itself would be compromised or those
sperm would not be available for fertilization. This also
implies that the frequency of the unrecombined events
could be theoretically higher, because gametes carrying
an imbalanced rearrangement could be selectively
eliminated.
If PhiC31 is being used as a standard driver (transgenic
or targeted) the possibility still remains that continuous
expression in a speciﬁc domain, which usually is the
domain under investigation, could lead to double-strand
breaks with consequent deleterious eﬀects. Another con-
cern is the recombination eﬃciency observed is only
 38% compared to Cre, suggesting that if PhiC31 is
used as a tissue-speciﬁc driver to delete a genomic
region, a higher level of mosaicism has to be expected.
For this reason, in order to improve PhiC31 eﬃciency
in vivo and especially to prevent attB deletions, it is impor-
tant to identify alternative attB sequence variants to
improve its eﬃciency compared to the wild-type attB
sequence in the mammalian genome. This report provides
a useful tool for mouse conditional mutagenesis and high-
lights the less desirable properties of PhiC31 that need
further improvement. One possibility readily available to
test is the codon-optimized PhiC31o sequence (24) that
demonstrated increased levels of recombination compared
to the wild-type sequence. This new PhiC31 sequence
along with the newly generated steroid-inducible PhiC31
(25) will be under scrutiny in the near future, in order to
test whether their eﬃciency and ﬁdelity will provide to the
scientiﬁc community a better tool for a more sophisticated
conditional mutagenesis approach.
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